Orexo's Upcoming Participation in Annual Healthcare Conference
Orexo Participates in Annual Healthcare Conference
Orexo AB (Publ.), which trades on both the Stockholm Stock Exchange under the ticker 'ORX' and has ADRs available on OTCQX (Ticker: ORXOY), is excited to announce its participation in Pareto Securities' 15th Annual Healthcare Conference. This significant event is scheduled for September 19 and will be held at the Downtown Camper by Scandic in the heart of the city.
Conference Details and Presentation
During the conference, Orexo will feature a presentation by Robert Rönn, Senior Vice President and Head of Research and Development (R&D). The presentation is set to take place between 2:25 PM and 2:45 PM CET in the Event Small room. Following this presentation, attendees will have opportunities for one-on-one meetings with Robert Rönn and Lena Wange, the Director of Investor Relations, allowing for deeper engagement and discussions about Orexo's innovative projects.
About Orexo
With nearly three decades of experience, Orexo has established itself as a notable player in the pharmaceutical industry by developing cutting-edge treatments that address significant medical needs. The company focuses on areas such as opioid use disorder, providing patients with necessary treatment solutions. Orexo's robust operations yield impressive net sales, reaching SEK 624 million in the last fiscal year, and the workforce comprises 126 dedicated employees.
Innovative Pharmaceuticals and Therapeutic Areas
Orexo is widely recognized for its commitment to introducing innovative therapeutic solutions across various medical fields. The company actively develops and commercializes products worldwide in partnership with leading organizations, ensuring that patients have access to the best treatment options available.
Financial Overview
The financial health of Orexo remains strong, as reflected in its net sales and strategic growth initiatives. Being listed on Nasdaq Stockholm, the company also offers its ADRs on OTCQX, enhancing accessibility for investors both locally and internationally.
Advanced Drug Delivery Technology: AmorphOX
A prominent feature of Orexo’s innovation portfolio is its AmorphOX® drug delivery technology. This advanced formulation system includes a unique blend of active ingredients and carrier materials, creating a stable amorphous composite that allows for rapid dissolution and efficient drug absorption. AmorphOX technology has shown promising results in various clinical studies, enhancing patient treatment experiences.
Clinical Studies and Validation
The efficacy of AmorphOX has been validated through numerous human clinical trials demonstrating its potential in improving drug exposure significantly. This technology caters to a broad spectrum of active ingredients, positioning Orexo at the forefront of pharmaceutical development.
Future Directions
With an eye on innovation, Orexo continues to expand its research efforts and explore new therapeutic domains. The ongoing commitment to addressing unmet medical needs ensures that Orexo remains a crucial player in the pharmaceutical landscape.
Connect with Orexo
For those interested in learning more about Orexo's latest developments, the company invites you to visit their official website at www.orexo.com. Additionally, Orexo is active on platforms like LinkedIn, X, and YouTube, offering updates on their initiatives and achievements.
Contact Information
For more inquiries, please reach out to:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
Phone: +46 18 780 88 00
Email: [email protected]
Frequently Asked Questions
What is Orexo's focus in the pharmaceutical industry?
Orexo specializes in developing innovative treatments, particularly for opioid use disorder, and is committed to addressing significant medical needs globally.
When will Orexo be presenting at the conference?
Orexo's presentation by Robert Rönn is scheduled for September 19, from 2:25 PM to 2:45 PM CET.
How can investors learn more about Orexo's financial performance?
Investors can visit Orexo's official website and access their financial reports and updates on their business activities.
What is the AmorphOX technology?
AmorphOX is Orexo’s proprietary drug delivery system that promotes rapid dissolution and stability of active pharmaceutical ingredients, validated through clinical studies.
Where can I find more information about Orexo's pipeline?
Detailed information regarding Orexo's product pipeline and developments can be found on their website and through their investor relations announcements.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Vitamins Market to Reach US$15.87 Billion by 2033
- Shortwave Infrared Market Growth Expected to Reach USD 350 Million
- Prime Mining Corp Reports High-Grade Drilling Expansion
- LanzaTech Partners with SEKISUI for Waste-to-Ethanol Innovation
- RadNet, Inc. to Present at an Upcoming Healthcare Conference
- Ensign Group Expands Reach with Seven New Facilities in Colorado
- Calibre Mining Reports Positive Results from Valentine Gold Mine
- Join the Class Action Against Lululemon Athletica Inc. Today
- NANO Nuclear Energy Inc. Class Action Lawsuit Update for Investors
- Class Action Lawsuit Notice for SeaStar Medical Investors
- Symbotic Inc. Investors Alert: Class Action Lawsuit Notice
- Current Legal Action Against Stellantis N.V. Investors - STLA
- Join the Class Action Against Indivior PLC (INDV) Now
- Legal Action Initiated for Ford Motor Company (F) Investors
- Citi Highlights Dire Challenges Facing China's Economy
- Markets Responding to Harris Opposition on U.S. Steel Deal
- Orthofix Medical Inc. Faces Class Action: Important Investor Update
- Partners Group Shares Drop as Earnings Miss Expectations
- MacroGenics, Inc. Investors Encouraged to Contact Legal Team
- Vicor Corporation Faces Class Action Lawsuit: Key Insights
- Levi & Korsinsky Urges Investors in Walgreens - Act Before Deadline
- Rolls-Royce Stock Rises Amid Cathay Pacific Engine Review
- Seritage Growth Properties Investors Alert: Class Action Lawsuit Update
- Class Action Alert: MongoDB Investors Urged to Act Before Deadline
- Global Equities Experience Continued Selling Pressure in Markets
Recent Articles
- Prime Mining Corp Reports High-Grade Drilling Expansion
- September Stock Market Challenges: Preparing Your Portfolio
- 21.co Launches Wrapped Bitcoin (21BTC) on Ethereum
- Plant-Based Meat Market Growth Expected to Reach $31.7 Billion
- Iridium Network: First to Use RayCare and TrueBeam Together
- Kronos Advanced Technologies Announces Special Cash Dividend
- Advantest Showcases Innovations in Semiconductor Testing Solutions
- Customer-Centric Strategies Drive Energy Transition Success
- Join BinSina Pharmacy in Celebrating 59 Years of Health
- Bank of Korea Predicts Stable Inflation in South Korea Ahead
- Warren Buffett: 2 Stocks on the Rise for Future Gains
- Why the 60/40 Portfolio Fails: Unlocking 8% Yields with ADX
- Explore Promising Biotech Stocks Worth Investing Right Now
- Interior Design Services Market Set to Reach $196.99 Billion
- Vaxcyte Webcast: Results of VAX-31 Vaccine Study
- Contactless Biometrics Technology Market Growth Insights
- Achieving Early Retirement with $1.5 Million
- Mastering Investment with Vanguard S&P 500 ETF
- Airbnb's Market Challenges and Growth Potential
- Alliance Trust PLC Announces Share Purchase Update
- Blackstone Expands European Warehouse Portfolio
- Super Micro Computer Plans 10-for-1 Stock Split: Invest Now?
- CV Depot Charging Market Set for Significant Growth
- CrowdStrike Reports Strong Earnings Amidst Outage Setbacks
- Kroma Achieves Series A Funding to Enhance Blockchain Solutions